KD025 Is a Casein Kinase 2 Inhibitor That Protects Against Glucolipotoxicity in β-Cells.
Saved in:
| Title: | KD025 Is a Casein Kinase 2 Inhibitor That Protects Against Glucolipotoxicity in β-Cells. |
|---|---|
| Authors: | Devkota R; Chemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, MA., Small JC; Chemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, MA., Carbone K; Chemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, MA., Glass MA; Chemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, MA., Vetere A; Chemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, MA., Wagner BK; Chemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, MA. |
| Source: | Diabetes [Diabetes] 2024 Apr 01; Vol. 73 (4), pp. 585-591. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: American Diabetes Association Country of Publication: United States NLM ID: 0372763 Publication Model: Print Cited Medium: Internet ISSN: 1939-327X (Electronic) Linking ISSN: 00121797 NLM ISO Abbreviation: Diabetes Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1939-327X |
|---|---|
| DOI: | 10.2337/db23-0506 |
